Siddhanta Medicity Ties Up with UK's SRAM & MRAM Group in a $108 Mn Stem Cell Therapy Advancement Goal 

The primary goal of this partnership is to advance the frontiers of medical science and enhance patient outcomes by harnessing the collective expertise and resources of both organisations. 

Siddhanta Medicity, a Bhopal-based healthcare institution, has partnered with the UK-based SRAM & MRAM Group.  

Further, this strategic partnership will also raise an investment of USD 108 million, signalling a significant step towards advancing clinical research and development in the field of NK Cell and Mesenchymal Stem Cell Therapies. 

The primary objective of this collaboration is to push the boundaries of medical science and improve patient outcomes by leveraging the combined expertise and resources of these two entities.  

This investment will also pave the way for Siddhanta Medicity to establish a network of state-of-the-art hospitals across India. 

NK Cell therapy, a cutting-edge approach to cancer treatment, harnesses the body's natural killer (NK) cells to target and destroy cancer cells. Meanwhile, Mesenchymal Stem Cell therapy holds immense promise in regenerative medicine, aiming to repair and regenerate damaged tissues and organs. 

The collaborative effort between Siddhanta Medicity and SRAM & MRAM Group aspires to conduct comprehensive clinical research, aiming to refine the understanding of NK Cell and Mesenchymal Stem Cell therapies.  

This research will encompass rigorous testing, analysis, and optimisation of these therapies to ensure their safety and effectiveness for a wide range of medical conditions. 

Speaking on this development, Dr Subodh Varsheny, MD of Siddhanta Medicity, highlighted the significance of the USD 108 million investment, stating, "The investment of USD 108 Million will play a pivotal role in establishing cutting-edge stem cell research centres, state-of-the-art treatment facilities, and advanced laboratories equipped with the latest technologies. This collaborative effort aims to bring together leading scientists, researchers, and medical professionals to accelerate the development of novel stem cell therapies tailored to address the specific healthcare needs of Indian patients." 

The SRAM & MRAM Group's strategic entry into the Indian market, in conjunction with CELLAAX, a distinguished biopharmaceutical firm renowned for its pioneering cellular therapy research and development, is set to initiate its operations within India. 

Dr. Sailesh Lachu Hiranandani, chairman of the SRAM & MRAM Group, noted the collaboration and the remarkable possibilities it presents in advancing stem cell treatment in India. He stated, "We are excited about the collaboration and the remarkable possibilities it presents in advancing stem cell treatment in India. This investment reaffirms our commitment to driving progress in healthcare, and together, we aim to make regenerative medicine more accessible to patients across the country." 

In another recent development, Dr Agarwal's Group of Eye Hospitals, a Chennai-based eye-care chain, secured $80 million (INR 650 Cr) from the renowned global private equity firm TPG Growth and the Singapore-based investment company Temasek.  

This financial infusion propels the acquisition of cutting-edge technologies in specialized eye care, paving the way for the expansion of their hospital network to over 300 facilities within the next three years.